<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097005</url>
  </required_header>
  <id_info>
    <org_study_id>P10-765</org_study_id>
    <nct_id>NCT01097005</nct_id>
  </id_info>
  <brief_title>Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections</brief_title>
  <official_title>Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taisho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of long-term treatment with clarithromycin in patients
      with Non-tuberculous Mycobacterial Pulmonary Infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The revised 2007 American Thoracic Society/Infectious Diseases Society of America
      guidelines recommend a clarithromycin-based combination therapy for treatment of
      Mycobacterium avium complex (MAC) lung disease and stipulate approximately 1 year of
      continuous treatment after bacilli negative conversion. However, supporting data are
      insufficient.

      Objectives: To obtain data on the clinical outcome of clarithromycin-based regimens by
      conducting a nationwide prospective study mainly of MAC lung disease.

      Methods: In accordance with the guidelines, patients were enrolled in this survey according
      to their chest radiographic findings and microbiologic test results. They were treated with a
      multi-drug regimen including clarithromycin, rifampicin, and ethambutol (clarithromycin
      -based regimen) until bacilli negative conversion on continual treatment for 1 year. Data
      were collected &quot;pre-administration,&quot; &quot;on the bacilli negative conversion,&quot; and &quot;at 6 months
      after the end of treatment.&quot;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bacilli Negative Conversion Rate</measure>
    <time_frame>During the treatment with clarithromycin, from 40 days to 1232 days</time_frame>
    <description>Number of participants who tested positive for Bacilli before treatment and converted to Bacilli Negative at any point during the treatment with clarithromycin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Evaluation Using the 4-rank Scale of &quot;Effective&quot;, &quot;Ineffective&quot;, &quot;Deterioration&quot;, or &quot;Impossible&quot; by the Investigator</measure>
    <time_frame>When treatment with clarithromycin is discontinued, from 40 days to 1232 days</time_frame>
    <description>Number of participants who evaluated for efficacy of clarithromycin with the 4-rank Scales (&quot;Effective&quot;, &quot;Ineffective&quot;, &quot;Deterioration&quot;, &quot;Impossible&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological Relapse Related to Duration of Clarithromycin Administration</measure>
    <time_frame>36 months</time_frame>
    <description>Number of patients who have bacteriological relapse related to duration of Clarithromycin (CLR) administration after initial negative conversion</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">466</enrollment>
  <condition>Mycobacterium Infections, Atypical</condition>
  <arm_group>
    <arm_group_label>Klaricid</arm_group_label>
    <description>Those with an exposure</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Pulmonary non-tuberculous mycoplasma infection and who are indicated for
        treatment with Klaricid
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients with Pulmonary non-tuberculous mycoplasma infection and who are indicated for
             treatment with Klaricid

        Exclusion Criteria

          -  Contraindications according to the package insert

          -  Patients with a history of hypersensitivity to any ingredient of Klaricid

          -  Patients who are receiving pimozide, ergot-containing products, or cisapride

          -  Patients who have AIDS (Acquired Immune Deficiency Syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Kato, MD., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Japan Co.,Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36460</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39122</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36463</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36470</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36471</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36472</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36473</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36474</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36475</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36482</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36465</name>
      <address>
        <city>Inzai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36483</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36484</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36485</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36486</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36487</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54466</name>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54468</name>
      <address>
        <city>Kobe</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36488</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36513</name>
      <address>
        <city>Kofu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39126</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36489</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36493</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39123</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54469</name>
      <address>
        <city>Maebashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36494</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36495</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36459</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36461</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54465</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37145</name>
      <address>
        <city>Obihiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36496</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36497</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39125</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28404</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36492</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36501</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54464</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36477</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36478</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36481</name>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36462</name>
      <address>
        <city>Seto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36503</name>
      <address>
        <city>Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36506</name>
      <address>
        <city>Shimotsuke</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36504</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36505</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36499</name>
      <address>
        <city>Takatsuki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 15101</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36507</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36508</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36509</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36510</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 42710</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54470</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36458</name>
      <address>
        <city>Toyohashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36511</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 37144</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 36512</name>
      <address>
        <city>Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 39124</name>
      <address>
        <city>Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <results_first_submitted>June 17, 2015</results_first_submitted>
  <results_first_submitted_qc>July 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2016</results_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mycobacterium Infections, Atypical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Please contact the investigator, and discuss with us.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients will be registered using a central registration system. The investigators will register eligible patients with the registration center via FAX by 7 days after initiation of clarithromycin treatment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clarithromycin</title>
          <description>Those with an exposure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="466">number of participants who were enrolled for this study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analysis of Safety</title>
              <participants_list>
                <participants group_id="P1" count="441">number of participants who could be measured for Adverse Events</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analysis of NTM Lung Disease</title>
              <participants_list>
                <participants group_id="P1" count="340">number of participants who contributed to the Baseline data</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analysis of Bacilli Negative Conversion</title>
              <participants_list>
                <participants group_id="P1" count="285">number of participants who were analysed for bacilli negative conversion</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Analysis of CGI</title>
              <participants_list>
                <participants group_id="P1" count="249">number of participants who were measured for Clinical Global Improvement (CGI)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="365"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Case Report Form not collected</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects cannot visit the hospital</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor medication compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No examination data available</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Deviation from exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuance by complication</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clarithromycin</title>
          <description>Those with an exposure</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bacilli Negative Conversion Rate</title>
        <description>Number of participants who tested positive for Bacilli before treatment and converted to Bacilli Negative at any point during the treatment with clarithromycin</description>
        <time_frame>During the treatment with clarithromycin, from 40 days to 1232 days</time_frame>
        <population>Analysis of the bacilli negative conversion</population>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin</title>
            <description>Negative conversion / Yes</description>
          </group>
        </group_list>
        <measure>
          <title>Bacilli Negative Conversion Rate</title>
          <description>Number of participants who tested positive for Bacilli before treatment and converted to Bacilli Negative at any point during the treatment with clarithromycin</description>
          <population>Analysis of the bacilli negative conversion</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Evaluation Using the 4-rank Scale of &quot;Effective&quot;, &quot;Ineffective&quot;, &quot;Deterioration&quot;, or &quot;Impossible&quot; by the Investigator</title>
        <description>Number of participants who evaluated for efficacy of clarithromycin with the 4-rank Scales (&quot;Effective&quot;, &quot;Ineffective&quot;, &quot;Deterioration&quot;, &quot;Impossible&quot;)</description>
        <time_frame>When treatment with clarithromycin is discontinued, from 40 days to 1232 days</time_frame>
        <population>Analysis of Clinical Global Improvement (CGI). Number of patients with each rank scale.</population>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin</title>
            <description>Those with an exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Evaluation Using the 4-rank Scale of &quot;Effective&quot;, &quot;Ineffective&quot;, &quot;Deterioration&quot;, or &quot;Impossible&quot; by the Investigator</title>
          <description>Number of participants who evaluated for efficacy of clarithromycin with the 4-rank Scales (&quot;Effective&quot;, &quot;Ineffective&quot;, &quot;Deterioration&quot;, &quot;Impossible&quot;)</description>
          <population>Analysis of Clinical Global Improvement (CGI). Number of patients with each rank scale.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ineffective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impossible to assess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bacteriological Relapse Related to Duration of Clarithromycin Administration</title>
        <description>Number of patients who have bacteriological relapse related to duration of Clarithromycin (CLR) administration after initial negative conversion</description>
        <time_frame>36 months</time_frame>
        <population>End of study (completers). Analysis of bacteriological relapse.</population>
        <group_list>
          <group group_id="O1">
            <title>Clarithromycin</title>
            <description>The subjects who completed the study</description>
          </group>
        </group_list>
        <measure>
          <title>Bacteriological Relapse Related to Duration of Clarithromycin Administration</title>
          <description>Number of patients who have bacteriological relapse related to duration of Clarithromycin (CLR) administration after initial negative conversion</description>
          <population>End of study (completers). Analysis of bacteriological relapse.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-14 months CLR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥15 months CLR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During treatment with clarithromycin up to 3.4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Clarithromycin</title>
          <description>Those with an exposure</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Alveoliltis allergic</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;possible&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>Causal relationship with the study drug was rated as &quot;Not related&quot; by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigators will be granted by sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Takao Miki, Medical Affairs</name_or_title>
      <organization>Mylan EPD Japan</organization>
      <email>takao.miki@mylan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

